Anzeige
Mehr »
Login
Montag, 04.11.2024 Börsentäglich über 12.000 News von 674 internationalen Medien
Sagenhafte +10.000 % Gewinnchance mit Spezialisten für KI-Cybersecurity!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A14M6X | ISIN: US04351P1012 | Ticker-Symbol: A71
Tradegate
04.11.24
13:04 Uhr
114,00 Euro
-2,00
-1,72 %
1-Jahres-Chart
ASCENDIS PHARMA A/S ADR Chart 1 Jahr
5-Tage-Chart
ASCENDIS PHARMA A/S ADR 5-Tage-Chart
RealtimeGeldBriefZeit
115,00117,0022:58
115,00117,0022:00

Aktuelle News zur ASCENDIS PHARMA Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
15:45Ascendis Pharma A/S's (ASND) Overweight Rating Reiterated at Cantor Fitzgerald5
13:10Ascendis Pharma and Novo Nordisk Sign Collaboration for Development and Commercialization of TransCon Technology-based Products in Metabolic and Cardiovascular Diseases177- Collaboration leverages Ascendis' proprietary TransCon technologies and Novo Nordisk's expertise in cardiometabolic diseases - Once-monthly GLP-1 receptor agonist will be the collaboration's...
► Artikel lesen
12:06Ascendis Pharma A/S - 6-K, Report of foreign issuer1
09.10.Ascendis Pharma A/S - 6-K, Report of foreign issuer6
08.10.Here's How Much You Would Have Made Owning Ascendis Pharma Stock In The Last 10 Years3
01.10.Ascendis Pharma submits sBLA for growth hormone deficiency therapy3
30.09.Ascendis Pharma beantragt FDA-Zulassung für Wachstumshormonbehandlung bei Erwachsenen2
30.09.Ascendis Pharma: New 3-Year Skeletal Dynamics Data for Adults with Hypoparathyroidism Treated with TransCon PTH (Palopegteriparatide) Presented at ASBMR 20241
30.09.Ascendis Pharma Announces Submission of Supplemental Biologics License Application to FDA for TransCon hGH for the Treatment of Adults with Growth Hormone Deficiency135COPENHAGEN, Denmark, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced it has submitted a supplemental Biologics License Application (sBLA) to the U.S. Food & Drug...
► Artikel lesen
24.09.Here's How Much You Would Have Made Owning Ascendis Pharma Stock In The Last 10 Years1
23.09.Ascendis Pharma A/S - 6-K, Report of foreign issuer1
20.09.Ascendis Pharma prices $300M equity offering3
20.09.Ascendis Pharma Prices Public Offering Of 2 Mln ADSs At $150.00/ADS1
20.09.Ascendis Pharma A/S Announces Pricing of Public Offering of ADSs2
19.09.Ascendis Pharma Commences Underwritten Public Offering Of $300 Mln Of ADSs-
18.09.Ascendis Pharma slips after $300 million share offering launch2
18.09.Ascendis Pharma startet öffentliches Angebot im Wert von 300 Millionen US-Dollar3
18.09.Ascendis Pharma launches $300 million public offering3
18.09.Ascendis Pharma A/S Announces Proposed Public Offering of ADSs100COPENHAGEN, Denmark, Sept. 18, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that it has commenced an underwritten public offering of $300,000,000 of American Depositary...
► Artikel lesen
17.09.Ascendis Pharma shares retain Outperform rating, Evercore ISI lifts target citing potential in new patient starts3
Seite:  Weiter >>
109 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1